Chronic Idiopathic Constipation Drugs Market Size, Share & Forecast Report - 2026 to 2030

The global chronic idiopathic constipation (CIC) drugs market has been projected to grow at the CAGR of 6.4% market during 2020-2027. The market is expected to reach up to $ 2973.3 million in terms of revenue by 2025.  The market is expected to show significant growth during the forecast period due to an increase in the geriatric population, modern dilatory habits lead to developing constipation, disease such as cancer leads to develop constipation, and strong pipeline molecule expected to drive the growth of CIC market worldwide.

Market Insights:

The global chronic idiopathic constipation (CIC) drugs market is significantly growing due to the growing prevalence of global chronic idiopathic constipation. It is estimated that more than 15% of the adult population in the United States and Europe is affected with chronic idiopathic constipation. The rising number of geriatric population, effective drugs in the pipeline and unhealthy dietary habits would drive the growth of CIC drugs market worldwide. Currently, medications such as Lubiprostone, Cisapride, Tegaserod, Prucalopride, Linaclotide, and Naloxone is the most widely used in the market. Plecanatide is newly approved by US-FDA and it is expected to create further growth opportunities in the market. It is observed that, in the base year 2016, Lubiprostone is most widely used in market, due to its proven efficiency and established safety profile. It is estimated that OTC drug market will continue to grow at the fastest CAGR during the forecast period because constipation is generally not considered as a disease and thus people are less likely to visit doctors to get prescription for constipation. Currently, North America is dominating the CIC drugs market, a higher number of the geriatric populations driving the growth of CIC market in North America. Significant unmet needs and increasing healthcare awareness would create significant opportunities for market players in the Asia Pacific.

Market Segment Insights:

The global chronic idiopathic constipation (CIC) drugs market for the purpose of the study is segmented on the basis of drug types and prescription type. Pipeline analysis (Elobixibat, Relenopride), Lubiprostone, and Linaclotide are the prime drugs considered in drug type segmentation. On the other hand, prescription drugs and over the counter drugs are considered in the prescription type segment.

Global Chronic Idiopathic Constipation (CIC) Drugs Market Segmentation:

By Drug Type, 2018–2027 ($ Millon)

• Lubiprostone
• Linaclotide
• Others
• Pipeline Drug Analysis: Elobixibat
• Pipeline Drug Analysis: Relenopride

By Prescription Type, 2018–2027 ($ Millon)

• Prescription Drugs
• Over the Counter Drugs

By Geography, 2018-2027 ($ Millon)

• North America
• Europe
• Asia Pacific
• Latin America (LATAM)
• Middle East and Africa (MEA)

Regional Insights:

For the purpose of this study, the global chronic idiopathic constipation (CIC) drugs market is regionally categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets. These regional markets are further sub-segmented into top country-level markets that majorly determine the regional industry trends. Among the considered regional markets, North America currently dominates the global chronic idiopathic constipation (CIC) drugs market, with United States being the largest county-level market due to the higher prevalence of chronic constipation, increase in the incidence of lifestyle respective diseases, and higher healthcare spending are predominantly driving the growth in the United States. On the other hand, Asia Pacific is anticipated to be the fastest-growing market for CIC drugs. Improvement in economic conditions in this region coupled with increasing healthcare awareness is the most prominent market driver in the region.

Market Competition Assessment:

The major players currently operating in the global CIC drugs market include Actavis, Bayer AG, Chugai Pharmaceutical, Ferring International Center S.A., GlaxoSmithKline, Ironwood Pharmaceuticals Inc., Pfizer, Progenics pharmaceuticals Inc., Roche Holding AG, Salix Pharmaceuticals Ltd., Sanofi, Sucampo Pharmaceuticals Inc., Synergy Pharmaceuticals.

List of Key Companies:

• Actavis
• Bayer AG
• Chugai Pharmaceutical
• Ferring International Center S.A.
• GlaxoSmithKline
• Ironwood Pharmaceuticals Inc.
• Pfizer
• Progenics pharmaceuticals Inc.
• Roche Holding AG
• Salix Pharmaceuticals Ltd.
• Sanofi
• Sucampo Pharmaceuticals Inc.
• Synergy Pharmaceuticals
• Other Major Players

Request a free report sample @ https://www.researchcorridor.com/request-sample/?id=69431